The early stages of the disease are largely asymptomatic; as a result, COPD is often diagnosed late, with more than three-quarters of individuals already having moderate or severe/very severe ...

Carpets, fireworks, and hot tubs are some of the unexpected things that can hurt your lungs. Find out what you can do to prevent problems from these and other culprits.

Verona的COPD药物商业化超预期的背后，折射出的是COPD适应症药物迭代的迫切需求，上一个时代的激素类药物和β受体激动剂都因为作用效果较为广谱而有众多副反应，针对PDE靶点的COPD药物已经初显峥嵘，之后还有TSLP靶点的单抗作为“预备队”，C ...

For people with chronic obstructive pulmonary disease (COPD), breathing is often front of mind because it can be difficult, and it gets worse over time. There is no cure yet for COPD, but experts ...

COPD requires regular monitoring through tests like spirometry to assess the condition’s severity and aid in an individualized treatment plan. COPD is a progressive lung condition that makes ...

A persistent, often progressive, lung disease, COPD results from chronic inflammation that leads to structural changes ...

Chronic obstructive pulmonary disease is a serious, progressive illness that hits the homeless and underinsured the hardest.

For the 16 million Americans with chronic obstructive pulmonary disease (COPD), travel can be as anxiety ... his Alaska cruise and saw the ship’s stage shows, while his wife and her friends ...

AstraZeneca’s respiratory drug Fasenra has failed in chronic obstructive pulmonary disease (COPD), in a market hotly contested by its UK rival GlaxoSmithKline. Fasenra (benralizumab), developed ...

Patients with COPD and type 2 diabetes using SGLT2i were much less likely to have ER visits and hospitalizations related to COPD exacerbations.

Currently, COPD-marketed therapy leaders include GSK’s Trelegy Ellipta, which is set to grow in sales to $2.16bn by 2033.

The monoclonal antibody added £1.7B ($2.2B) in revenue for the company in 2023 with ~16% YoY growth. More on GSK GSK's Q2 ...